Targeted Oncology

Rationale for Evaluating Ceritinib in ALK-Positive Patients With NSCLC

Laura Quan Man Chow, MD, FRCPC, director of the Thoracic, Head and Neck Cancer, and Clinical Immunotherapy Programs, and associate cancer center director for clinical research, The University of Texas at Austin, discusses the rationale for evaluating ceritinib (Zykadia) in patients with ALK-positive non–small cell lung cancer (NSCLC) in the ASCEND-7 trial. This phase II clinical trial was 1 of the first studies dedicated to investigating the activity of a targeted agent in the brain, as well as to measure and assess the brain activity, says Chow.

Read more

OncLive

Dr. Kerrigan on Sequencing Challenges in ALK+ NSCLC

Katie Kerrigan, MD, a hematology/oncology fellow at Huntsman Cancer Institute, University of Utah School of Medicine, discusses sequencing challenges in the treatment of patients with ALK-positive non–small cell lung cancer. One of the biggest challenges that needs to be addressed with future research has to do with determining the optimal sequencing of available agents, says Kerrigan. Patients with ALK-mutated disease often live a long time, and there are no overall survival data available for the available second- and third-generation ALK TKIs, Kerrigan adds. Understanding how best to sequence these agents is necessary to provide patients with the maximum benefit for the longest period of time.

Read more

OncLive

Immunotherapy Efforts Forge Ahead in Stage III NSCLC

The shift in standard of care, based on results from the phase III PACIFIC trial, continue to underscore the role of immunotherapy for patients with stage III unresectable non–small cell lung cancer (NSCLC), said Gregory M. M. Videtic, MD, CM, FRCPC.

Read more

OncLive

Update on NDA in GIST, Promising Data in Lung Cancer, KRAS G12C-Mutant Cancers, and AML, and European Approval in RCC

Today- An update on a new drug application, promising findings in lung cancer, KRAS G12C–mutant cancers, and acute myeloid leukemia, and a European approval in renal cell carcinoma. Welcome to OncLive News Network! I’m Gina Columbus. The FDA intends to split proposed indications for avapritinib into two separate new drug applications for patients with gastrointestinal stromal tumor. The applications would be split into one for patients with PDGFRA exon 18–mutant disease regardless of prior therapy, and one for fourth-line GIST. Additionally, the FDA has requested topline findings from the phase III VOYAGER trial of avapritinib versus regorafenib in the third- or fourth-line setting for patients with GIST.

Read more

OncLive

Dr. Wozniak on Sequencing Immunotherapy in Lung Cancer

Antoinette Wozniak, MD, FACP, FASCO, associate director of clinical research, and medical oncologist, at University of Pittsburgh Medical Center Hillman Cancer Center, discusses sequencing with immunotherapy and chemoradiation in select patients with stage III lung cancer. Current standard practice in this specific setting includes giving immunotherapy after chemoradiation, typically after patients recover from the chemoradiation treatment, explains Wozniak. In previous trials, patients who were able to receive immunotherapy sooner after chemoradiation often responded better, but that group of patients could have been in better shape, says Wozniak. Ongoing studies are examining giving chemoradiation concurrently with immunot...

Read more

BioSpace

Biohaven Statement Regarding Kleo Pharmaceuticals (Kleo): Thomas J. Lynch, Jr., MD, Appointed As Kleo Chairman Of The Board

NEW HAVEN, Conn., Nov. 4, 2019 /PRNewswire/ -- Biohaven Pharma Holding Company Ltd. (NYSE: BHVN) a clinical-stage biopharmaceutical company provided an update regarding the appointment of Thomas J. Lynch, Jr., MD, as Chairman of the Board at Kleo Pharmaceuticals. Biohaven's current ownership interest in outstanding stock of Kleo is 41.9%. Vlad Coric, M.D., CEO of Biohaven, commented, "Tom is a world-renowned oncologist and clinical researcher who has devoted his career to advancing cancer therapies.

Read more

BioSpace

White House Nominates MD Anderson’s Stephen Hahn as Next FDA Commissioner

IgorGolovniov / Shutterstock It’s now official. Stephen Hahn, chief medical executive of the University of Texas MD Anderson Cancer Center, will be nominated as the next commissioner of the U.S. Food and Drug Administration (FDA). Hahn had been the frontrunner for the top spot at the FDA. Late Friday, President Donald Trump put forth Hahn’s name to take over the top spot of the nation’s regulatory agency as the permanent replacement for Commissioner Scott Gottlieb, who retired earlier this year.

Read more

BioSpace

Clinical Catch-Up: October 28-Nov 1

Even clinical trial announcements don’t slow down for Halloween. It was a typically busy week. Here’s a look. Y-mAbs Therapeutics provided a clinical update on its omburtamab for central nervous system (CNS) leptomeningeal metastases from neuroblastoma and several other cancer indications. The updated readout as of June 30, 2019 from a single-center study of patients who received up to two doses of radiolabeled omburtamab showed that of the 107 patients who could be evaluated, the median survival had increased to 50.8 months.

Read more

BioSpace

Pre-Clinical Research News | BioSpace

Get news straight to your inbox by signing up for our free eNewsletters BiomX To Present at Plenary Session of the AASLD Liver Conference BiomX’s Chief Medical Officer, Sailaja Puttagunta, M.D., will present pre-clinical data from the company’s liver program at the plenary session of the American Association for The Study of Liver Diseases (AASLD) taking place in Boston, Massachusetts from November 8 - November 12, 2019. Harbour BioMed Announces Initiation of First-in-human Study of Next-generation Anti-CTLA-4 Antibody for Treatment of Solid Tumors HBM4003 is the First Fully Human Heavy Chain Only Antibody Ever to Enter Human Trials Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ENaC at the North American Cystic Fibrosis Conf...

Read more

BioSpace

ORYX Provides Strategic Update on the Clinical Development of Oncolytic Virotherapy ParvOryx

Endorsement of pivotal development program in recurrent glioblastoma (rGBM) from both EMA and FDA Munich (Germany), November 4, 2019: ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today provided an update on the development strategy for oncolytic virus ParvOryx, a wild type rat oncolytic parvovirus (H-1PV). So far, two Phase I/IIa clinical trials in recurrent glioblastoma (rGBM) and metastatic, inoperable pancreatic cancer have been completed successfully.

Read more

BioSpace

Biodesix Announces First System-Wide Integration of Nodify XL2 Testing for Lung Nodule Management

BOULDER, Colo.--( BUSINESS WIRE)-- Biodesix, Inc. the leader in lung cancer diagnostics, today announced that Tri-Star Health in Nashville, TN, the region's largest, most comprehensive healthcare provider, is the first hospital system in the U.S. to adopt the recently launched Nodify XL2™ proteomic nodule classifier for incidental lung nodule management. 1.6 million lung nodules are detected incidentally each year in the U.S., but fewer than five percent turn out to be malignant. In order to prevent unnecessary invasive diagnostic procedures, Tri-Star Health has adopted routine Nodify XL2 testing to help stratify patients by risk of malignancy using a simple blood draw. This press release features multimedia.

Read more

BioSpace

Hillstream BioPharma Announces Collaboration with Ardena to Support QUATRAMER ManufacturingAlignment Reinforces Hillstream BioPharma's Strategy to Partner with Top-Tier Firms

CHESTER, N.J., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (“Hillstream”) today announced a collaboration with Ardena to secure manufacturing feasibility and capacity for Hillstream’s QUATRAMER portfolio. This includes HSB-1216, a novel formulation of salinomycin encapsulated within the QUATRAMER technology, a potent cancer stem cell inhibitor with initial indications for small cell lung cancer. “Our strategic collaboration with Ardena represents our continued commitment to produce and provide the highest quality product to patients,” said Randy Milby, president and CEO of Hillstream BioPharma.  “We believe HSB-1216 has the potential to address the unmet needs of the small cell lung cancer patient population.

Read more

BioSpace

Tecentriq Continues Upward Projection by Proving Efficacy Over and Over

lucarista / Shutterstock Roche's Tecentriq, generically known as Atezolizumab, is a monoclonal antibody which influence in the medical community has steadily risen for the past four years. The versatile drug currently treats locally advanced or metastatic urothelial carcinoma, metastatic non-small cell lung cancer, metastatic triple-negative breast cancer, and extensive-stage small cell lung cancer. Tecentriq is designed to bind with a protein called PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors.

Read more

Targeted Oncology

Investigator Perspectives - Non Hodgkin Lymphoma | Targeted Oncology

Select a Topic: – Select a topic –Bladder CancerBreast CancerChronic Lymphocytic LeukemiaColorectal CancerFollicular LymphomaGeneral CancerGraft versus Host DiseaseKidney CancerLung CancerMultiple MyelomaNon-Hodgkin LymphomaProstate CancerSkin Cancer Browse by Series: – Select a Series –

Read more

MedPageToday

Gut Bacteria May Promote Bowel Cancer

People who harbored certain genera of intestinal bacteria were more likely to develop colorectal cancer (CRC), an international study found. In the first analysis to use Mendelian randomization to investigate the causal role of bacteria in CRC, Kaitlin H. Wade, PhD, of the University of Bristol in the United Kingdom, and colleagues reported that the presence in the microbiome of 13 microbial strains in unclassified genera within the order Bacteroidales increased odds of diagnosis with CRC by 8% (odds ratio 1.08, 95% CI 1.02-1.15, P=0.02). "Our findings support previous studies that have shown that Bacteroidales bacteria are more likely to be present, and in larger quantities, in individuals with bowel cancer compared to those without the ...

Read more

Al Jazeera

'Delhi in ICU': Spike in respiratory diseases due to toxic smog

New Delhi, India - A blanket of toxic smog engulfed India's capital this week, with air quality crossing dangerous levels and causing a public outcry. A slight improvement was recorded in Delhi's air on Monday when the government rolled out an odd-even numberplate scheme to limit traffic, putting almost 1.5 million private vehicles off the city's roads. On Tuesday, the city's air quality index (AQI) of 411 was still in the "severe" category. The safe limit specified by the World Health Organization is 60. More: More than 40 million people living in and around Delhi have suffered from the poisonous air as politicians indulged in a blame game and, in some instances, offered bizarre solutions. As the city wheezed, India's environment m...

Read more

Dove Press

Targeting ZEB2 By microRNA-129 In Non-Small Cell Lung Cancer Suppresse

Xingtao Li,1 Chunhong Li,2 Hongmei Bi,3 Shufang Bai,4 Lin Zhao,5 Jing Zhang,6 Chunhui Qi7 1Department of Clinical Laboratory, Jinan City People’s Hospital, Laiwu 271100, People’s Republic of China; 2Department of Public Health, Jinan Zhangqiu District Hospital of TCM, Jinan 250200, People’s Republic of China; 3Department of Respiratory Medicine, The Third People’s Hospital of Qingdao, Qingdao 266041, People’s Republic of China; 4Department of Ultrasound, The People’s Hospital of Zhangqiu Area, Jinan 250200, People’s Republic of China; 5Department of Respiratory Medicine, People’s Hospital of Rizhao, Rizhao 276826, People’s Republic of China; 6Department of Cardiothoracic Vascular Surgery, People’s Hospital of Rizhao, Rizhao 276826, Peop...

Read more

Annals of Internal Medicine

Life-Gained–Based Versus Risk-Based Selection for Lung Cancer Screening | Annals of Internal Medicine | American College of Physicians

Note: Dr. Cheung had full access to all of the data in the study and final responsibility for the decision to submit the manuscript for publication. Financial Support: By the Intramural Research Program of the National Cancer Institute, National Institutes of Health. Disclosures: Dr. Cheung reports that he previously coauthored a manuscript proposing the Lung Cancer Death Risk Assessment Tool model. Dr. Berg reports consultancies for GRAIL and Medial EarlySign and reports that she is the chair of the Policy Task Group of the American Cancer Society National Lung Cancer Roundtable.

Read more

Annals of Internal Medicine

Cost-Effectiveness of U.S. Lung Cancer Screening | Annals of Internal Medicine | American College of Physicians

Acknowledgment: The authors thank E.J. Feuer for scientific input and critical review of the work. Grant Support: This study is based on research conducted by the NCI's CISNET (NCI grant U01-CA199284). Disclosures: Dr. ten Haaf reports nonfinancial support from the International Association for the Study of Lung Cancer Strategic Screening Advisory Committee, grants from Sunnybrook Health Sciences (Toronto, Canada) and the University of Zurich, and grants and nonfinancial support from the NELSON screening program outside the submitted work.

Read more

Dove Press

RNA m6A Methyltransferase METTL3 Promotes The Growth Of Prostate Cance

Prostate cancer (PC), which occurs in the prostate, is one of the most common cancers in men.1 Among American men, PC is the second leading cause of death, with an estimated incidence of 174,650 new cases and 31,620 deaths according to the American Cancer Society statistic 2019. The majority of PC patients are treated with surgical removal of the prostate, radiation, chemotherapy, or hormonal therapy. Despite the improvement of these therapies, the five years’ recurrence for prostate cancer patients is still about 25%.2 Invasion is one of the most important factors responsible for lethal, the survival rate decreased significantly if tumor has metastasized since diagnose.

Read more

Dove Press

Prognostic Significance Of The Inflammatory Index-Based Scoring System | CMAR

Multiple myeloma (MM) is a malignant plasmocyte disease that accounts for 10% of hematopoietic tissue tumors and 1% of all malignancies.1 It is the common malignant hematologic tumor.2 MM is characterized by clonal proliferation of malignant plasma cells in bone marrow and excessive secretion of monoclonal immunoglobulins in the blood and/or in urine.3 In recent years, with advancing biological-targeted therapy and the development of new drugs, the treatment and prognosis of MM has improved greatly.

Read more

Dove Press

MicroRNA-769-5p Promotes The Growth Of Glioma Cells By Targeting Lysin

Glioma is one of the most serious leading causes of cancer-related mortality worldwide.1 Glioblastoma multiforme (GBM), a malignant grade IV tumor, is the most aggressive type of glioma, which accounts for 60–70% of all gliomas.2 Surgical resection remains the main choice of glioma treatment, but the clinical outcome for glioma patients remains poor.3 Hence, there is an urgent need to identify both novel sensitive biomarkers for diagnosis and new therapeutic targets for treatment in glioma. MicroRNAs (miRNAs) are single-stranded non-coding RNAs that bind to the 3ʹ untranslated region (3ʹUTR) of target mRNAs to induce degradation and interfere in the translation process.4 More and more studies provide evidence to support that miRNAs are abe...

Read more

Dove Press

Clinical Significance And Integrative Analysis Of Kinesin Family Membe

Lung cancer is one of the most prevalent malignancies and is a major leading cause of cancer-related death worldwide.1 As the main pathological subtype of lung cancer, lung adenocarcinoma (LUAD) has high morbidity and poor outcomes. Great improvements have been made in LUAD diagnosis and treatment over the past decade, but the long-term survival rate of patients with LUAD is still low.2 Although high-throughput sequencing analysis has facilitated genetic and epigenetic research in lung cancer, the molecular mechanisms involved are not yet fully elucidated. Kinesin superfamily proteins (KIFs) are a class of microtubule-dependent molecular motor proteins.3 They share a conserved motor domain and participate in some intracellular and extracel...

Read more

Dove Press

HGF/MET Regulated Epithelial-Mesenchymal Transitions And Metastasis By

Jun Yin,1,* Weimin Hu,2,* Wenfan Fu,1 Lu Dai,1 Zeyong Jiang,1 Shengpeng Zhong,1 Boyun Deng,1 Jian Zhao1 1Department of Chest Surgery, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong 510095, People’s Republic of China; 2Department of Abdominal Surgery, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong 510095, People’s Republic of China *These authors contributed equally to this work Correspondence: Jian Zhao Department of Chest Surgery, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong 510095, People’s Republic of China Email HGF/MET has been found to be associated with non-small cell lung canc...

Read more

Cancer Discovery

Case Made for MCLA-128 against NRG1 Fusion–Positive Cancers

Abstract Two patients with KRAS–wild-type pancreatic ductal carcinoma and NRG1 fusions received the bispecific antibody MCLA-128, which led to tumor shrinkage. One experienced a partial response and the other had stable disease. A third patient with non–small cell lung cancer and an NRG1 fusion also experienced a partial response in a clinical proof-of-concept study. ©2019 American Association for Cancer Research.

Read more

Nature

Genomic analysis of primary and recurrent gliomas reveals clinical outcome related molecular features

A total of 81 glioma specimens from 80 patients were collected in this study, including 64 primary and 17 recurrent surgical resected tumors, two of which were matched. The clinical characteristics of samples were summarized in Table 1. It is worth noting that despite different clinical features, the patient distribution was similar between primary and recurrent gliomas, thus allowing us to better evaluate and compare the genomic features between the groups. The genomic analysis was performed using hybrid capture based targeted sequencing.

Read more

Nature

Trends in clinical development for PD-1/PD-L1 inhibitors

PD-1/PD-L1-targeted monoclonal antibodies (mAbs) are now the standard of care for 16 different types of cancer and tissue-agnostic indication. Since our first PD-1/PD-L1 trial landscape survey conducted in September 2017 (Ann. Oncol. 24, 84–89; 2019), 23 additional approvals have been granted to PD-1/PD-L1 mAbs by the FDA, and 4 new PD-1 mAbs have reached the market, bringing the total on the global market to 9. These achievements were powered by some of the largest clinical trial programmes ever in oncology.

Read more

Nature

A novel small-molecule inhibitor of trefoil factor 3 (TFF3) potentiates MEK1/2 inhibition in lung adenocarcinoma

H1299 and H1975 cells were used as lung non-small cell ADC models due to their moderate mRNA expression of TFF3 based on the results of the expression of TFF3 in 11 human lung ADC cell lines published previously24. Thus, the potential oncogenic functions of TFF3 could be determined through both forced or depleted expression of TFF3 in H1299 and H1975 cells. Stable cell lines with forced expression of TFF3, H1299-TFF3, and H1975-TFF3 and respective vector-transfected control cell lines were established.

Read more

Nature

Association of select vitamin D receptor gene polymorphisms with the risk of tobacco-related cancers – a meta-analysis

Genetic alterations in important cell biochemical pathways may play roles in cancer development together with environmental or lifestyle factors15. Likewise, tobacco-related cancers are strongly dependent on environmental factors and habits such as tobacco smoking, and air pollution are also influenced by some genetic factors13,36. Recently, one of the most intensively studied genes in connection to the risk of cancers has been that of the vitamin D receptor. Vitamin D has been reported to regulate the expression of over 150 metabolic genes, and vitamin D deficiency may be correlated with a higher risk of developing cancers, diabetes, and autoimmune or cardiovascular diseases16.

Read more

Nature

Pathologists meet their match in tumour-spotting algorithm

Artificial-intelligence technology that examines images of lung tissue can identify two common lung cancers just as well as pathologists do. A team led by Narges Razavian and Aristotelis Tsirigos at the New York University School of Medicine trained and tested a convolutional neural network — a deep-learning algorithm that is adept at processing images — on 1,634 images of cancerous and healthy lung tissue. The algorithm identified healthy cases and distinguished as accurately as three pathologists between two common types of lung cancer: adenocarcinoma and squamous-cell carcinoma. The researchers also trained the network on adenocarcinoma images that had been labelled with the mutations underlying the cancer.

Read more

Yahoo Finance

Regeneron Provides Updates on Phase 3 Libtayo® (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer

TARRYTOWN, N.Y., Nov. 5, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today provided an update on the ongoing Phase 3 development program evaluating Libtayo® (cemiplimab), a PD-1 inhibitor, as monotherapy and combination therapy in first-line patients with advanced non-small cell lung cancer (NSCLC). Regeneron is currently recruiting patients in two Phase 3 trials in first-line NSCLC. The first trial, an open-label randomized trial that compares Libtayo monotherapy to standard-of-care platinum-based chemotherapy in patients with high PD-L1 expression (tumor proportion score [TPS] 50%): The second trial, which consists of two parts, evaluates Libtayo in combination with platinum-based chemotherapy: Libtayo is being ...

Read more

Yahoo Finance

US Navy Veterans Lung Cancer Advocate Now Launches a National Initiative to Identify Navy Veterans or People with Asbestos Exposure Lung Cancer and They Recommend the Law Firm of Karst von Oiste to Assist with Compensation

NEW YORK, Nov. 4, 2019 /PRNewswire/ -- The US Navy Veterans Lung Cancer Advocate says, "We are urging a US Navy Veteran or person with asbestos exposure lung cancer anywhere in the nation or their family to call us anytime at 800-7214-0303. We want to ensure a Navy Veteran or person with asbestos exposure lung cancer receives the best possible compensation results. Most people with asbestos exposure lung cancer do not realize the asbestos trust funds were set up for them along with people with mesothelioma.

Read more

Yahoo Finance

Genprex Issues Lung Cancer Prevention Measures in Support of Lung Cancer Awareness Month

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, is publishing lung cancer prevention measures in an effort to educate the public, prevent new cases and raise awareness of lung cancer while supporting November’s Lung Cancer Awareness Month. Each patient’s cancer is unique, but there are some preventive efforts that can be made to lower the risk of getting lung cancer. The following are preventive actions that may lower the risk of getting lung cancer: According to the World Health Organization, lung cancer is the leading cause of cancer deaths worldwide, causing more deaths than breast, colon, kidney, liver, prostate or skin cancers, and lung cancer is one of the most common types of cancer.

Read more

Forbes

The Women Who Helped Shape LBJ’S Administration

The play The Great Society takes place after Lyndon B. Johnson has won a landslide presidential election. His administration was at the epicenter of a monumental era that would transform history. The Civil Rights Movement was generating serious heat. There were the deaths of Martin Luther King Jr. and Robert F. Kennedy. The war in Vietnam was spiraling out of control. Barbara Garrick and Brian Cox in the play The Great Society Matthew Murphy At a time when women were expected to remain silent in the background, some strong women helped shape the Johnson administration.

Read more

This is Money

Strauss hopes Flower can blossom in England after leaving ECB

Sir Andrew Strauss would not be surprised to see Andy Flower secure a high-profile coaching role in the future and hopes he remains involved in English cricket. The duo were central to England winning the 2010-11 Ashes in Australia and becoming the number one Test side in the world a year later. However, the England and Wales Cricket Board confirmed last month Flower would bring his 12-year spell with the ECB to an end after time as England assistant coach and head coach, plus a lengthy period as coach of the England Lions. Strauss told the PA news agency: “Andy was by far the best coach I ever worked with, a great man and had incredible success with the England cricket team. “We certainly haven’t seen the end of Andy Flower yet.

Read more

Yahoo Finance

Mirati Therapeutics Reports Third Quarter 2019 Financial Results

SAN DIEGO, Nov. 4, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, 2019. "The recent data presented demonstrate that MRTX849 treatment can result in clinical responses at well tolerated doses. We believe that MRTX849 clinical combinations, including the combination of MRTX849 with TNO155 in our collaboration with Novartis, will significantly increase the eligible patient population," said Charles M.

Read more

Yahoo Finance

The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo

Chicago, IL – November 4, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer PFE, Merck MRK, Bristol-Myers BMY and Glaxo GSK. Here are highlights from Friday’s Analyst Blog: Pfizer, Merck, Bristol-Myers, Glaxo and Bayer released their third-quarter results this week. In other important news, AstraZeneca’s (AZN) first-line lung cancer study on Imfinzi showed positive results. Recap of the Week’s Most Important Stories: Earnings Update: Pfizer, Merck, Bristol-Myers and Glaxo beat estimates for both earnings and sales.

Read more

Yahoo Finance

Hillstream BioPharma Announces Collaboration with Ardena to Support QUATRAMER Manufacturing

CHESTER, N.J., Nov. 04, 2019 (GLOBE NEWSWIRE) -- (“Hillstream”) today announced a collaboration with Ardena to secure manufacturing feasibility and capacity for Hillstream’s QUATRAMER portfolio. This includes HSB-1216, a novel formulation of salinomycin encapsulated within the QUATRAMER technology, a potent cancer stem cell inhibitor with initial indications for small cell lung cancer. “Our strategic collaboration with Ardena represents our continued commitment to produce and provide the highest quality product to patients,” said Randy Milby, president and CEO of Hillstream BioPharma.  “We believe HSB-1216 has the potential to address the unmet needs of the small cell lung cancer patient population.

Read more

Yahoo Finance

MAX BioPharma Announces Key Update to its Oncology Program and Oxysterol Lead Drug Candidates that Target Tumorigenic Signaling Pathways

LOS ANGELES, Nov. 4, 2019 /PRNewswire/ -- MAX BioPharma, Inc. (www.maxbiopharma.com) recently published two articles describing its anti-tumorigenic oxysterol lead compounds in the peer-reviewed journal, Cells.  Oxy186 and Oxy210 are derived from the Company's Oxysterol Therapeutics® platform of proprietary oxysterols. MAX BioPharma is currently optimizing the compounds for oral dosing and performing pre-clinical studies required by the FDA for clinical development and commercialization. MAX BioPharma's anti-tumorigenic oxysterol, Oxy186, inhibits the Hedgehog signaling pathway, which is dysregulated and activated in many human tumors including pancreatic and lung cancers.

Read more

Roche

Lung cancer awareness month: An evolution

Every person affected by lung cancer has their own unique story to tell.

Read more

Twitter

Oncology Learning Network nsclc: 04/11/2019 15:01:23

True or False? PFS rates with erlotinib therapy plus bevacizumab for EGFR-positive NSCLC were superior to those seen with erlotinib monotherapy in a phase 2 study by Stinchcombe et al. #nsclc Take the quiz and test your knowledge: https://t.co/UhWu0DgMsa

Read more

Twitter

JAMA Oncology LCSM: 04/11/2019 16:00:00

Randomized phase 2 trial of erlotinib +/- bevacizumab in EGFR mutant NSCLC. Combination did not result in superior PFS, ORR or OS

Read more

Twitter

UPMC Physician Resources : 04/11/2019 16:00:09

James Herman, MD, from @UPMCHillmanCC, discusses the work that has been done to elucidate biomarkers of response to immunotherapy and the necessity of molecular testing at diagnosis.

Read more

Twitter

Antibody News : 04/11/2019 16:32:03

Osimertinib With or Without Bevacizumab for EGFR Mutant Nonsmall Cell Lung Cancer With Leptomeningeal Metastasis: Leptomeningeal metastasis LM is a devastating and terminal complication of advanced nonsmallcell lung cancer NSCLC especially in patients…

Read more

Twitter

The ASCO Post lcsm, oncology, cancer, immunotherapy: 04/11/2019 18:32:00

Solange Peters, MD, PhD, on NSCLC: CheckMate 227 Trial of Nivolumab/Ipilimumab vs Chemotherapy https://t.co/GmZfWTRg31 #lcsm #oncology #cancer #immunotherapy

Read more

Twitter

Renal Cell Carcinoma : 04/11/2019 23:24:02

Immunotherapy Efforts Forge Ahead in Stage III NSCLC: Gregory M. M. Videtic MD CM FRCPC discusses ongoing developments with immunotherapy in stage III non–small cell lung cancer.

Read more

Twitter

Andres F. Cardona : 05/11/2019 00:52:34

The same reality for pts with EGFR+ NSCLC in Colombia. For 1000 NSCLC pts tested with NGS the gain is 34465.48 QALY´s. Each untested pt loses 19 QALY’s, which corresponds to about 19,000 QALY’s / year. It is necessary to unblind our country, the precision oncology is necessary https://t.co/zuH2gjuS0R

Read more

Twitter

ImmunotherapyPapers : 05/11/2019 07:39:01

Immunotherapy Efforts Forge Ahead in Stage III NSCLC

Read more

Twitter

OncLive.com lcam, lcsm: 05/11/2019 11:10:06

Gregory M. M. Videtic, MD, CM, FRCPC, of @ClevelandClinic discusses ongoing developments with immunotherapy in stage III NSCLC #lcam #lcsm

Read more